登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06505824,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically and/or cytologically confirmed locally advanced or metastatic solid tumors that are incurable or currently have no standard treatment;
入选标准第 5 条
Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib);
入选标准第 3 条
Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;
入选标准第 9 条
Anthracycline cumulative dose > 360 mg/m2 in previous (new) adjuvant therapy;
排除标准第 16 条
ECOG 0 or 1;
入选标准第 8 条
Must have at least one measurable lesion according to RECIST v1.1 definition;
入选标准第 7 条
Other malignant tumors diagnosed within 5 years before the first dose;
排除标准第 6 条
HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
排除标准第 17 条
Pregnant or lactating women;
排除标准第 20 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06505824,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily sign the informed consent and follow the requirements of the protocol; No gender limit; Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib); Expected survival time ≥3 months; Histologically and/or cytologically confirmed locally advanced or metastatic solid tumors that are incurable or currently have no standard treatment; Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 2 years; Must have at least one measurable lesion according to RECIST v1.1 definition; ECOG 0 or 1; Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0; No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; The level of organ function must meet the requirements on the premise that blood transfusion is not allowed within 14 days before the screening period and no cell growth factor drugs are allowed; Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN; The urine protein + 2 or 1000 mg / 24 h or less or less; For premenopausal women with fertility may have to 7 days before beginning treatment for a pregnancy test, serum pregnancy must be negative, and must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.排除标准:Exclusion Criteria:
Anti-tumor therapy such as chemotherapy or biological therapy has been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil; Prior receipt of an ADC drug with a TOPI inhibitor as a toxin; History of severe heart disease or cerebrovascular disease; QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia; Active autoimmune and inflammatory diseases; Other malignant tumors diagnosed within 5 years before the first dose; Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 100 mmHg); A history of ILD requiring steroid therapy, or current ILD or grade ≥2 radiation pneumonitis according to the RTOG/EORTC definition, or suspicion of such a condition during screening; Complicated pulmonary diseases leading to clinically severe respiratory function impairment; Patients with massive or symptomatic effusions or poorly controlled effusions; Imaging examination showed that the tumor had invaded or wrapped around the chest, neck, pharynx and other large blood vessels; Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded; Symptoms of active central nervous system metastasis; Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any excipients of BL-M14D1; Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT); Anthracycline cumulative dose > 360 mg/m2 in previous (new) adjuvant therapy; HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection; Active infection requiring systemic therapy with serious infection within 4 weeks before informed consent; There were indications of pulmonary infection or active pulmonary inflammation within 2 weeks before informed consent; Participated in another clinical trial within 4 weeks before the first dose; Pregnant or lactating women; A history of severe neurological or psychiatric illness; Severe unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent; Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent; History of intestinal obstruction, inflammatory bowel disease, or extensive bowel resection or presence of Crohn's disease, ulcerative colitis, or chronic diarrhea; Patients scheduled for vaccination or receiving live vaccine within 28 days before the first dose; Other conditions for participation in the trial were not considered appropriate by the investigator.
引自 ClinicalTrials.gov, NCT06505824, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06505824,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。